Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). Conference Paper uri icon

authors

  • Reardon, David A
  • Kaley, Thomas Joseph
  • Dietrich, Jorg
  • Lim, Michael
  • Dunn, Gavin P
  • Gan, Hui Kong
  • Cloughesy, Timothy Francis
  • Clarke, Jennifer Leigh
  • Park, Andrew J
  • Macri, Mary J
  • Ryan, Aileen
  • Ricciardi, Toni
  • Reddy, Vijay
  • Venhaus, Ralph Rudolph

publication date

  • May 20, 2016